{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"100.0"},{"groupId":"OG002","value":"100.0"},{"groupId":"OG003","value":"100.0"}]}],"title":"1 or more (1+) AE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7"},{"groupId":"OG001","value":"75.0"},{"groupId":"OG002","value":"85.7"},{"groupId":"OG003","value":"100.0"}]}],"title":"1+ AE related to pomalidomide"},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3"},{"groupId":"OG001","value":"37.5"},{"groupId":"OG002","value":"78.6"},{"groupId":"OG003","value":"80.0"}]}],"title":"1+ severity grade 3-4 AE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3"},{"groupId":"OG001","value":"25.0"},{"groupId":"OG002","value":"42.9"},{"groupId":"OG003","value":"70.0"}]}],"title":"1+ severity grade 3-4 AE related to pomalidomide"},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0"},{"groupId":"OG001","value":"12.5"},{"groupId":"OG002","value":"42.9"},{"groupId":"OG003","value":"30.0"}]}],"title":"1+ serious AE (SAE)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"12.5"},{"groupId":"OG002","value":"7.1"},{"groupId":"OG003","value":"10.0"}]}],"title":"1+ SAE related to pomalidomide"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"21.4"},{"groupId":"OG003","value":"0.0"}]}],"title":"1+ AE leading to discontinuation of pomalidomide"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7"},{"groupId":"OG001","value":"75.0"},{"groupId":"OG002","value":"42.9"},{"groupId":"OG003","value":"80.0"}]}],"title":"1+AE-dose reduction/interruption of pomalidomide"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"37.5"},{"groupId":"OG002","value":"28.6"},{"groupId":"OG003","value":"70.0"}]}],"title":"1+related AE-reduction/interruption of pomalidomid"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"10"}],"units":"Participants"}],"description":"Relation to study drug was assessed by the Investigator as either suspected or not suspected. Counts represent the suspected relationship. Severity was assessed using National Cancer Institute Common Toxicity Terminology Criteria for Adverse Events version 3.0 (NCI CTCAE v3.0): 1= Mild 2= Moderate 3= Severe 4= Life-threatening and 5= Death related to AE. Serious AEs (SAEs) are those that resulted in death, were life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly, or resulted in an important medical event that may have jeopardized the patient or required medical or surgical intervention to prevent one of the outcomes listed above.\n\nData collection is ongoing and future data results will be included as available.","groups":[{"description":"Pomalidomide 2 mg daily on days 1-21 of each 28-day cycle. Upon PD, participants had the option of discontinuing treatment or adding dexamethasone.","id":"OG000","title":"Phase 1: 2 mg Pomalidomide"},{"description":"Pomalidomide 3 mg daily on days 1-21 of each 28-day cycle. Upon PD, participants had the option of discontinuing treatment or adding dexamethasone.","id":"OG001","title":"Phase 1: 3 mg Pomalidomide"},{"description":"Pomalidomide 4 mg daily on days 1-21 of each 28-day cycle. Upon PD, participants had the option of discontinuing treatment or adding dexamethasone.","id":"OG002","title":"Phase 1: 4 mg Pomalidomide"},{"description":"Pomalidomide 5 mg daily on days 1-21 of each 28-day cycle. Upon PD, participants had the option of discontinuing treatment or adding dexamethasone.","id":"OG003","title":"Phase 1: 5 mg Pomalidomide"}],"paramType":"NUMBER","populationDescription":"Safety population.\n\nData collection is ongoing and future data results will be included as available.","reportingStatus":"POSTED","timeFrame":"Up to week 104","title":"Phase 1: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) While on Single-Agent Pomalidomide as of the 01 April 2011 Cut-off","type":"SECONDARY","unitOfMeasure":"percentage of participants"}